Cormedix (CRMD) closed at $4.66 on November 13, 2026, down 3.7% from the previous close, on volume of 2,188,899 shares (30-day average 1,640,016).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 30, 2026 | Diagonal Put Spread | 18-Dec-26 : 21-Jan-289 : 8 P | 500 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
CorMedix Earnings Call Highlights Heron Deal and DefenCath Outlook
TipRanks (Sun, 15-Nov 12:11 AM ET)
Heron’s 18.3% Stake in Cormedix Raises Governance Risks and Potential Valuation Overhang
TipRanks (Fri, 13-Nov 1:01 AM ET)
CorMedix GAAP EPS of -$0.19 misses by $0.08, revenue of $54.52M beats by $1.75M
Seeking Alpha News (Thu, 12-Nov 7:34 AM ET)
Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 12-Nov 7:30 AM ET)
Here are the major earnings before the open Thursday
Seeking Alpha News (Wed, 11-Nov 6:00 PM ET)
Seeking Alpha News (Wed, 11-Nov 12:03 PM ET)
CorMedix Announces Agreement to Acquire Heron’s Commercial Assets
TipRanks (Tue, 10-Nov 6:18 PM ET)
TipRanks (Tue, 10-Nov 7:40 AM ET)
TipRanks (Tue, 10-Nov 7:01 AM ET)
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Cormedix trades on the NASDAQ stock market under the symbol CRMD.
As of November 13, 2026, CRMD stock price declined to $4.66 with 2,188,899 million shares trading.
CRMD has a beta of 0.65, meaning it tends to be less sensitive to market movements. CRMD has a correlation of 0.01 to the broad based SPY ETF.
CRMD has a market cap of $370.36 million. This is considered a Small Cap stock.
Last quarter Cormedix reported $55 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.08.
In the last 3 years, CRMD traded as high as $17.43 and as low as $2.57.
The top ETF exchange traded funds that CRMD belongs to (by Net Assets): VTI, AVUV, IWM, VXF, XPH.
CRMD has underperformed the market in the last year with a price return of -58.4% while the SPY ETF gained +13.4%. CRMD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -42.8% and -18.2%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
CRMD support price is $4.63 and resistance is $5.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRMD shares will trade within this expected range on the day.
